fitforthem
about

scope and guide to the platform

—research groups

research groups network graph visualization

—repositories

catalog of the institutional repositories

—heritage

selection of collections, museum, cultural sites and ancient books

By continuing your visit to this site, you accept the use of essential cookies.

Read more
6533b85afe1ef96bd12b9e21

RESEARCH PRODUCT

Natalizumab Discontinuation after the 24th Course: Which Is Way? The TY-STOP Study

Marinella ClericoStefania MercantiFederico PiazzaDario GnedVincenzo Brescia MorraRoberta LanzilloLuca AmatoMario QuarantelliAngelo GhezziAnna BianchiDamiano BaronciniMarco GibbinJoseph VargasGiuseppe SalemiSabrina RealmutoMaria Teresa FerroFrancesca VitettaPatrizia SolaDamiano PaolicelliMaria TrojanoLuca Durelli

subject

Multiple SclerosisNatalizumab multiple sclerosisNatalizumabSettore MED/26 - NeurologiaMRi
yearjournalcountryeditionlanguage
2013-01-01
http://hdl.handle.net/10447/73012
EU flag

FORTHEM European University Alliance is co-funded by the European Union. FIT FORTHEM has received funding from the European Union's Horizon 2020 Research and Innovation Programme under grant agreement No. 101017248. The content of this website represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission.

University of Jyväskylä logoUniversity of Jyväskylä's websiteUniversity of Burgundy logoUniversity of Burgundy's websiteUniversity of Mainz logoUniversity of Mainz's websiteUniversity of Palermo logoUniversity of Palermo's websiteUniversity of Latvia logoUniversity of Latvia's website
University of Agder logoUniversity of Agder's websiteUniversity of Opole logoUniversity of Opole's websiteUniversity of Sibiu logoUniversity of Sibiu's websiteUniversity of València logoUniversity of València's website
FORTHEM logoFORTHEM alliance's website